References
- AbramsPCardozoLFallM2002The standardization of terminology of lower urinary tract function: report from the standardization sub-committee of the international continence societyNeurourol Urodynam2116778
- AlbertiIGrenierAKrausH2005Pharmaceutical development and clinical effectiveness of a novel gel technology for transdermal drug deliveryExpert Opin Drug Deliv29355016296788
- AppellRAChancellorMBZobristRH2003Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjectsMayo Clin Proc7869670212934778
- ChappleCKhullarVGabrielZ2005The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysisEur Urol4852615885877
- DavilaGWDaughertyCASandersSWTransdermal Oxybutynin Study Group2001A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinenceJ Urol166140511435842
- DmochowskiRRDavilaGWZinnerNRTransdermal Oxybutynin Study Group2002Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinenceJ Urol168580612131314
- DmochowskiRRSandPKZinnerNRTransdermal Oxybutynin Study Group2003Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinenceUrology622374212893326
- DmochowskiRRNittiVStaskinD2005Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trialsWorld J Urol232637016151816
- MilsomIAbramsPCardozoL2001How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence studyBJU Int87760611412210
- NewmanDK2003Patient perceptions on new therapeutic options for the control of overactive bladderPoster presented at the 34th Annual Conference of SUNAMarch 26–30San Antonio, TX, USA
- RuscinJMStaskinDRSandPK2004Dose modulation of oxybutynin transdermal system for overactive bladderThe Consultant Pharmacist19938
- SandPKGoldbergRLucenteV2005Decreased sexual function in patients with overactive bladder: interim results from the matrix studyJ Pelvic Med Surg1183
- StewartWFVan RooyenJBCundiffGW2003Prevalence and burden of overactive bladder in the United StatesWorld J Urol203273612811491
- Watson Pharma2003Oxytrol Product InformationWatson Pharma, IncMorristown, NJ, USA
- ZinnerNRDavilaGAndersonRP2004Dose modulation using oxybutynin transdermal system for overactive bladder in older adultsJ Am Geriatr Soc52S767
- ZobristRHSchmidBFeickA2001Pharmacokinetics of the Rand S-enantiomers of oxybutynin and N-desethyloxybutynin following oral and transdermal administration of the racemate in healthy volunteersPharm Res1810293411496941
- ZobristRHQuanDThomasHM2003Pharmacokinetics and metabolism of transdermal oxybutynin: in vitro and in vivo performance of a novel delivery systemPharm Res20103912608543